GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (STU:X0M1) » Definitions » Short Interest

XOMA (STU:X0M1) Short Interest


View and export this data going back to 1986. Start your Free Trial

What is XOMA Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of XOMA's Short Interest

For the Biotechnology subindustry, XOMA's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XOMA's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA's Short Interest distribution charts can be found below:

* The bar in red indicates where XOMA's Short Interest falls into.


XOMA (STU:X0M1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (STU:X0M1) » Definitions » Short Interest
Comparable Companies
MRSN PSTX XERS AGEN INO MGNX EPIX RVNC INZY CRMD OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
XOMAO.PFD:USA XOMAP.PFD:USA XOMA:USA X0M1:Germany
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
Website
https://www.xoma.com
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

XOMA (STU:X0M1) Headlines

No Headlines